Company: OCEA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-011080
Chunk: 184

Company: Ocean Biomedical, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 184
---
 the interdisciplinary expertise and resources
required to develop and commercialize a diverse portfolio of assets. We are organized around a licensing and subsidiary structure that
we believe will enable us to create mutual value both for us and potential licensing partners. We believe this structure, combined with
the professional networks of our leadership team members, allows us to opportunistically build a continuous pipeline of promising product
innovations through our existing and potential future relationships with research institutions.

Our goal is to optimize value
creation for each of our product candidates, and we intend to continuously assess the best pathway for each as it progresses through the
preclinical and clinical development process—including through internal advancement, partnerships with established companies and
spinouts or other strategic transactions—in order to benefit patients through the commercialization of these products. Our current
active assets are licensed from Brown University and Rhode Island Hospital. Our scientific co-founders and members of our Board of Directors
(“Board”), Dr. Jack A. Elias and Dr. Jonathan Kurtis, are both affiliated with Brown University and with Rhode Island Hospital.
Our strategy is to accelerate the flow of the academic discoveries, and the required clinical development required for these product candidates
and advance them commercially. The number of potential opportunities at research universities and medical centers is large, but only a
small fraction of these opportunities is currently tapped in the market. The gap remains wide, and we believe this presents an attractive
opportunity for us to become an industry leader by addressing a need to accelerate the advancement of therapeutics that can address significant
unmet medical needs. The core elements that we believe differentiate our business model include:

    ●
    Harnessing inventions and technologies from research universities and medical centers. We are experienced at identifying and sourcing breakthrough discoveries at academic and research institutions, including our current partnerships with Brown University and Rhode Island Hospital.

35

    ●
    Developing new drug therapies through an operationally efficient, evidence-based and milestone-driven approach. Once we select an asset for development, we pursue what we believe are appropriate development strategies that we aim to execute efficiently by leveraging contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”), and other drug development experts and consultants.

    ●
    Building a diverse portfolio of product candidates. We are evidence-based and program agnostic, meaning that our resources are driven strictly by program progress and milestone achievements. Our approach is to develop multiple diverse programs in parallel which mitigates business risk.

    ●
    Providing attractive economic upside to our partners at research universities and medical centers